Drug Approval | July 04, 2023
Lupin receives approval from FDA for Cyanocobalamin Nasal Spray
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
Menon has over 41 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry
Once the unit is made fully functional, it will help the company in increasing its API and intermediate production capacity
Subscribe To Our Newsletter & Stay Updated
